Astrazeneca plc ADR (AZN) concluded trading on Thursday at a closing price of $67.30, with 6.85 million shares of worth about $460.94 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -5.78% during that period and on May 08, 2025 the price saw a loss of about -3.95%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.
Stock saw a price change of -4.55% in past 5 days and over the past one month there was a price change of 3.70%. Year-to-date (YTD), AZN shares are showing a performance of 2.72% which decreased to -11.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.24 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 6.09 million. The stock is currently trading -2.48% below its 20-day simple moving average (SMA20), while that difference is down -6.66% for SMA50 and it goes to -8.31% lower than SMA200.
Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 16.74% of that.
The stock has a current market capitalization of $208.72B and its 3Y-monthly beta is at 0.40. PE ratio of stock for trailing 12 months is 27.04, while it has posted earnings per share of $2.49 in the same period. Its PEG reads 2.42 and has Quick Ratio of 0.70 while making debt-to-equity ratio of 0.77. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.84% while standing at 2.46% over the month.
Stock’s fiscal year EPS is expected to rise by 9.64% while it is estimated to increase by 12.93% in next year. EPS is likely to shrink at an annualized rate of 11.16% for next 5-years, compared to annual growth of 34.63% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on April 15, 2025 offering an Outperform rating for the stock and assigned a target price of $75 to it. Stock get a Hold rating from Deutsche Bank on November 06, 2024.
